HDL-Atherosclerosis Treatment Study (HATS)

• Status: Completed
• Trial end date: 2001-02-01

Summary

To measure the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.

• Phase: Phase 3

Details

• Lead Sponsor: University of Washington
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Antioxidants; Niacin; Simvastatin